CA-SYNACK
28.5.2019 07:50:07 CEST | Business Wire | Press release
Synack, the most trusted Crowdsourced Penetration Testing company, announced today it is now both CREST Accredited for penetration testing services and a CREST Member company in the USA. This is further recognition of Synack as the market leader in delivering the most effective, efficient penetration test.
CREST is a not-for-profit accreditation and certification body that represents and supports the technical information security market. CREST was set up in 2006 in response to the clear need for more regulated professional services with known, dependable quality, and is now recognized globally as the cyber assurance body for the technical security industry. CREST has become the respected standard for penetration testing in countries across the world, where it is increasingly a mandatory requirement for companies that have the most stringent security requirements such as government and financial services. Synack has researchers in more than 60 of these countries.
“This accreditation demonstrates that Synack’s crowdsourced penetration testing follows well-established best practices while using software and the world’s best security researchers,” said Dr. Mark Kuhr, Synack CTO and co-founder. “CREST’s accreditation examination determines if an organization meets its risk assessment, technical capability, and code of conduct standards. The CREST organisation clearly understands the challenges enterprises face today in scaling their security practices, and is supporting the G2000 by accrediting Synack to support these challenges. We appreciate the acknowledgement that Synack meets all of those critical requirements.”
Synack has prioritized trust, quality and insights as critical characteristics of a penetration test. The accreditation process determines if an organization meets risk assessment, technical capability, and code of conduct standards. Relative to a traditional penetration test, Synack believes that the crowdsourced approach provides additional testing rigor, enhanced technology, and deeper visibility and control.
“The CREST accreditation provides further recognition of Synack penetration testing, offering the highest levels of technical quality and testing rigor“ said David Charlton, Synack’s Chief Product Strategist and former Head of Penetration Testing at JPMorgan Chase & Co.
Not only does CREST offer an independent, third party assessment of a company’s penetration testing capabilities, it also provides researchers with the opportunity to become CREST qualified researchers. Synack’s crowd includes CREST certified penetration testers. Synack exposes its elite, global security researcher community in 60+ countries to the benefits of CREST. CREST offers a structured entry point for penetration testers globally and could serve as a significant stepping stone to members of the Synack’s Red Team. Synack looks forward to working closely with members of its global community seeking CREST qualifications.
This accreditation is another pillar showing that Synack takes trust seriously. Companies gain intelligence and efficiency by utilizing Synack to address vulnerabilities in a more efficient and effective way while maintaining a strong security posture. Those that work with Synack and use Crowdsourced Penetration Testing for 2+ years are up to 200% more secure than those that do not or have less than a year of usage.
Today, Synack secures >$1 trillion in Fortune 500 revenue, 75% of the top credit card companies, Top 10 consulting firms and security companies, and over 50% of federal cabinet-level agencies. Synack has received awards including 2019 Cyber Defender by CB Insights, CIO Review’s 20 Most Promising Enterprise Security Solution Providers, The Software Report’s Top 25 CyberSecurity Companies, and Wealthfront’s 2019 Career-Launching Companies.
About Synack
Synack, the most trusted crowdsourced security company, delivers comprehensive and continuous penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create a scalable, effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005215/en/
Contact:
Ellie McCardwell, Synack Communications Email: press@synack.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom